Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference
Guardant Health (Nasdaq: GH) announced its participation in the 39th Annual J.P.
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.
Guardant Health’s management is scheduled to present on Monday, January 11 at 7:50 a.m. Pacific Time / 10:50 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.guardanthealth.com.
About Guardant Health
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.
Source: Guardant Health, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201230005327/en/